Sota J, Girolamo M, Frediani B, Tosi G, Cantarini L, Fabiani C
Ophthalmol Ther. 2021; 10(4):777-813.
PMID: 34476773
PMC: 8589879.
DOI: 10.1007/s40123-021-00393-8.
Feizi S, Roshandel D
J Ophthalmic Vis Res. 2019; 14(2):195-210.
PMID: 31114657
PMC: 6504727.
DOI: 10.4103/jovr.jovr_86_18.
Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos P
Drug Des Devel Ther. 2019; 13:667-680.
PMID: 30858697
PMC: 6387597.
DOI: 10.2147/DDDT.S166092.
Gomez-Gomez A, Loza E, Rosario M, Espinosa G, de Morales J, Herreras J
Medicine (Baltimore). 2017; 96(42):e8045.
PMID: 29049193
PMC: 5662359.
DOI: 10.1097/MD.0000000000008045.
Ratay M, Bellotti E, Gottardi R, Little S
Adv Healthc Mater. 2017; 6(23).
PMID: 29034584
PMC: 5915344.
DOI: 10.1002/adhm.201700733.
An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.
McNally T, Damato E, Murray P, Denniston A, Barry R
Orphanet J Rare Dis. 2017; 12(1):130.
PMID: 28716038
PMC: 5513401.
DOI: 10.1186/s13023-017-0681-6.
The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.
Dart J
Eye (Lond). 2017; 31(2):301-332.
PMID: 28106896
PMC: 5306467.
DOI: 10.1038/eye.2016.284.
Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics.
Chu L, Annex B, Popel A
Front Pharmacol. 2015; 6:179.
PMID: 26379552
PMC: 4548203.
DOI: 10.3389/fphar.2015.00179.
Pharmacotherapy for uveitis: current management and emerging therapy.
Barry R, Nguyen Q, Lee R, Murray P, Denniston A
Clin Ophthalmol. 2014; 8:1891-911.
PMID: 25284976
PMC: 4181632.
DOI: 10.2147/OPTH.S47778.
Immunopathogenesis of ocular Behçet's disease.
Park U, Kim T, Yu H
J Immunol Res. 2014; 2014:653539.
PMID: 25061613
PMC: 4100451.
DOI: 10.1155/2014/653539.
Immunotherapeutic strategies in autoimmune uveitis.
Papotto P, Marengo E, Sardinha L, Goldberg A, Rizzo L
Autoimmun Rev. 2014; 13(9):909-16.
PMID: 24833504
PMC: 4181827.
DOI: 10.1016/j.autrev.2014.05.003.
Pharmacotherapy of scleritis: current paradigms and future directions.
Beardsley R, Suhler E, Rosenbaum J, Lin P
Expert Opin Pharmacother. 2013; 14(4):411-24.
PMID: 23425055
PMC: 3888795.
DOI: 10.1517/14656566.2013.772982.
Ocular manifestation of rheumatoid arthritis-different forms and frequency.
Zlatanovic G, Veselinovic D, Cekic S, Zivkovic M, dordevic-Jocic J, Zlatanovic M
Bosn J Basic Med Sci. 2010; 10(4):323-7.
PMID: 21108616
PMC: 5489043.
DOI: 10.17305/bjbms.2010.2680.
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.
Heiligenhaus A, Thurau S, Hennig M, Grajewski R, Wildner G
Graefes Arch Clin Exp Ophthalmol. 2010; 248(11):1531-51.
PMID: 20737162
DOI: 10.1007/s00417-010-1485-8.
High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
Sen H, Levy-Clarke G, Faia L, Li Z, Yeh S, Barron K
Am J Ophthalmol. 2009; 148(5):696-703.e1.
PMID: 19664754
PMC: 2922905.
DOI: 10.1016/j.ajo.2009.06.003.
Intravenous daclizumab for recalcitrant ocular inflammatory disease.
Bhat P, Castaneda-Cervantes R, Doctor P, Foster C
Graefes Arch Clin Exp Ophthalmol. 2009; 247(5):687-92.
PMID: 19198869
DOI: 10.1007/s00417-009-1043-4.
Treatment strategies in mucous membrane pemphigoid.
Neff A, Turner M, Mutasim D
Ther Clin Risk Manag. 2008; 4(3):617-26.
PMID: 18827857
PMC: 2500254.
DOI: 10.2147/tcrm.s1140.
Biologic agents in the management of inflammatory eye diseases.
Michalova K, Lim L
Curr Allergy Asthma Rep. 2008; 8(4):339-47.
PMID: 18606088
DOI: 10.1007/s11882-008-0054-2.
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
Yeh S, Wroblewski K, Buggage R, Li Z, Kurup S, Sen H
J Autoimmun. 2008; 31(2):91-7.
PMID: 18571896
PMC: 2742388.
DOI: 10.1016/j.jaut.2008.05.001.
[Mucous membrane pemphigoid with ocular involvement. Part II: therapy].
Meyer-Ter-Vehn T, Schmidt E, Zillikens D, Geerling G
Ophthalmologe. 2008; 105(4):405-19.
PMID: 18392628
DOI: 10.1007/s00347-008-1700-8.